We advised the underwriters on a public equity offering

Davis Polk advised the representatives of the underwriters in connection with the $230.3 million offering of 4,899,000 shares of common stock of REGENXBIO Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “RGNX.”

Based in Rockville, Maryland, REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay, and associate Yoojin Nairn-Kim. The intellectual property and technology transactions team included counsel Bonnie Chen and associates Jay Frankel and Shuang Ci. The tax team included partner Mario J. Verdolini and associate Dov Sussman. All members of the Davis Polk team are based in the New York office.

Copy link to share post